Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

TAC01 HER2

Next Previous
Drug Profile

TAC01 HER2

Alternative Names: HER2-TAC01; TAC01-HER2

Latest Information Update: 21 Jun 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Triumvira
  • Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Gastric cancer; Solid tumours

Most Recent Events

  • 06 Jun 2024 Triumvira Immunologics terminates a phase-I/II TACTIC-2 trial in Gastric cancer and Solid tumours (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy, Combination therapy) in USA, Canada (IV) due to sponsors commercial decision (NCT04727151)
  • 20 Oct 2023 Efficacy and adverse events data from the phase I/II TACTIC-2 trial in Solid tumours presented at the48th European Society for Medical Oncology Congress(ESMO-2023)
  • 11 Oct 2023 Efficacy and adverse events data from the phase I/II TACTIC-2 trial in Solid tumours presented at the International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top